 Applied Genetic Technologies Corporation NASDAQ: AGTC has announced additional data from the ongoing X-linked retinitis pigmentosa XLRP gene therapy Phase 12 trial, including 12-month data from Groups 5 6 and 24-month data from two of three Group 4 patients. Groups 5 and 6 had a 50 response rate among patients who met the inclusion criteria for the Skyline and Vista trials. 